![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MEDIGENE AG AGREES TO BUY U.K.'S AVIDEX LIMITED FOR $64.2 MILLION IN SHARES
MEDIGENE AG AGREES TO BUY U.K.'S AVIDEX LIMITED FOR $64.2 MILLION IN SHARES
September 1, 2006
The biotechnology company MediGene AG announced today that it has signed an agreement on the acquisition of the privately held biotechnology company Avidex Ltd. based in Oxford, UK. With this acquisition,
MediGene will diversify and broaden its drug pipeline with several drug candidates
to treat cancer and autoimmune diseases, and will add a proprietary technology
platform to further fuel its future drug pipeline.
BioSpace
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct